Test Price
2,800 AEDโ Home Collection Available
P2RX2 Gene Progressive Hearing Loss Genetic Test in UAE
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily 8 AM โ 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance with a Consultant Medical Geneticist.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced genetic test screens for pathogenic variants in the P2RX2 gene, which is linked to autosomal dominant progressive sensorineural hearing loss. The test provides accurate molecular diagnosis to guide early intervention, genetic counselling, and family planning. Next Generation Sequencing (NGS) is used exclusively on the P2RX2 gene, ensuring high analytical sensitivity and specificity.
| Feature | Our P2RX2 NGS Test | Closest Alternative (Standard Exome) |
|---|---|---|
| Precision | Targeted gene sequencing, >99.9% analytical sensitivity | Whole exome coverage, incidental findings possible |
| Method | NGS on P2RX2 gene only | Exome sequencing, many genes analyzed |
| Turnaround Time | 3 to 4 Weeks | 8 to 12 Weeks |
Physician Insight & Safety Protocols
"This targeted test identifies the specific genetic cause of progressive hearing loss linked to the P2RX2 gene. Interpretation must be integrated with clinical audiometry and otoscopy. I strongly recommend post-test genetic counselling to tailor a lifelong hearing management plan. Your journey toward clarity begins with precise molecular insight and compassionate care."
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Clinical Advisory & Medication Safety
โ ๏ธ Medication Warning: Do not discontinue any prescribed medication or hearing aid without consulting your doctor. This test does not provide immediate treatment advice; it serves as a diagnostic tool.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients unable to provide informed consent; minors require guardian consent as per Federal Decree-Law No. 4 of 2016 on Medical Liability. Not indicated for individuals seeking non-hearing loss genetic screening.
- Emergency Red Flags: If you experience sudden, severe hearing loss with vertigo, acute ear pain, or facial weakness, seek immediate emergency care โ do not wait for genetic test results.
- Pregnant patients may be tested on clinicianโs recommendation; no fetal risks are associated with maternal blood draw.
Patient FAQ & Clinical Guidance
1. What does the P2RX2 genetic test detect, and who should consider it?
This targeted NGS identifies pathogenic DNA variants in the P2RX2 gene that cause autosomal dominant progressive sensorineural hearing loss, typically manifesting in childhood or early adulthood. It is recommended for individuals with a family history of early-onset hearing loss and for diagnostic confirmation prior to cochlear implant candidacy evaluation.
2. How is the sample collected, and is it painful?
A certified phlebotomist collects a small venous blood sample or a capillary blood drop via an FTA card using a painless finger prick. Collection can be performed at your home, office, or hotel. The sample is transported in a temperature-controlled cold-chain container to our ISO 9001:2015 accredited laboratory. No fasting or special preparation is required.
3. How quickly will I receive my results, and how are they explained?
Results are delivered within 3 to 4 weeks via a secure online portal. A complimentary telephonic consultation with a clinical geneticist is provided to translate the genetic findings into actionable clinical guidance. A printed report in English is also available.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance: This service adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Genetic data is anonymized, stored on local encrypted servers, and handled solely by DHA-licensed professionals. Patient consent follows Federal Decree-Law No. 4 of 2016 on Medical Liability.
Accreditation: ISO 9001:2015 Certified Laboratory (Cert: INT/EGQ/2509DA/3139). DHA Facility License: 1143. Laboratory Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | P2RX2 Gene Progressive Hearing Loss Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Whole Blood or Capillary Blood (FTA Card) |
| Methodology Used | Next Generation Sequencing (NGS) โ Targeted Gene Analysis |
| ICD-10-CM Code | H90.3 (Bilateral sensorineural hearing loss) |
| LOINC Code | 21663-4 (Gene mutation analysis) |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians